EVT-201

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
EVT-201
EVT-201.svg
Systematic (IUPAC) name
7-Chloro-3-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-5-methyl-4,5-dihydro-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one
Identifiers
CAS Number 308239-86-3
ATC code None
PubChem CID: 9885841
ChemSpider 8061514
Chemical data
Formula C17H17ClN6O2
Molecular mass 372.809 g/mol
  • Clc4cccc3n2cnc(c1nc(on1)CN(C)C)c2CN(C(=O)c34)C
  • InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
  • Key:JCYLWUVDHLVGER-UHFFFAOYSA-N

EVT-201 is a benzodiazepine derivative drug and partial positive allosteric modulator of the benzodiazepine site of the GABAA receptor.[1] It has 2–4-fold higher functional affinity for the α1 subunit relative to the α2, α3, and α5 subunits and significantly less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs.[2] Despite the lower efficacy, EVT-201 still shows effectiveness in the treatment of insomnia, and it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination.[2] The drug was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia.[2] As of 2007, EVT-201 has completed phase II clinical trials for this indication, with positive findings reported.[3] As of August, 2015, Phase II development is ongoing in China.[4]

References

  1. Lua error in package.lua at line 80: module 'strict' not found.
  2. 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'strict' not found.
  3. Lua error in package.lua at line 80: module 'strict' not found.
  4. Lua error in package.lua at line 80: module 'strict' not found.

<templatestyles src="Asbox/styles.css"></templatestyles>